| Drug development in higher-risk myelodysplastic syndromes |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Current and emerging strategies for management of myelodysplastic syndromes |
|
Blood reviews |
Myelodysplastic Syndromes (MDS) |
| Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency |
|
Blood Transfusion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood, cells, molecules & diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
